The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. The latest episode features Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology biological products and on providing CDMO services through its Scinai Bioservices business unit.

To begin the interview, Reichman discussed Scinai Immunotherapeutics’ business model.

“Scinai is developing its own innovative pipeline of biological therapeutic products based on a unique technology of VHH single domain antibodies originating from alpacas,” he said. “The antibodies are licensed from the Max Planck Institute and the University Medical Centre Göttingen, both in Germany. The two principal investigators with whom who we work are Professor Dirk Görlich and Professor Matthias Dobbelstein.”

Join IBN’s Carmel Fisher and Amir Reichman, CEO of Scinai Immunotherapeutics, to learn more about the company’s recent milestones.

Tune in to her Scinai CEO Amir Reichman in his interview with Adam Sarhan on the Smart Money Circle Show.

In this insightful discussion, Amir shares his entrepreneurial journey and vision for Scinai's future growth, including the company's cutting-edge innovations in plaque psoriasis treatment. He explains how Scinai is uniquely positioned to address the unmet needs of mild to moderate plaque psoriasis patients and outlines the strategic growth of the CDMO business unit, highlighting its crucial role in the company's expansion.

Amir also shares invaluable advice for biotech leaders and entrepreneurs, discussing business best practices, dos and don'ts, and common mistakes to avoid.